Landos Biopharma, Inc. (LABP) Social Stream



Landos Biopharma, Inc. (LABP): $22.93

0.13 (+0.57%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add LABP to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#202 of 360

in industry

LANDOS BIOPHARMA INC (LABP) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering LANDOS BIOPHARMA INC.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-10-20 6 $50 $15 $32.833 $4.391 647.73%
2021-11-16 6 $50 $15 $30 $4.391 583.22%
2022-01-03 4 $50 $7 $28.666 $4.391 552.84%
2022-03-24 6 $50 $7 $26.166 $4.391 495.9%
2022-04-12 6 $50 $1.4 $21.4 $4.391 387.36%
2022-05-12 6 $50 $0.8 $24.16 $4.391 450.22%
2022-05-13 6 $50 $0.8 $18.2 $4.391 314.48%
2022-08-12 5 $50 $0.8 $17.933 $4.391 308.4%
2022-11-11 3 $2 $0.2 $1.1 $4.391 -74.95%
2023-02-08 3 $2 $0.1 $1.05 $4.391 -76.09%
2023-03-24 2 $2 $0.1 $1.05 $4.391 -76.09%
2023-05-12 1 $10 $10 $10 $4.391 127.74%
2023-05-16 2 $10 $1 $5.5 $4.391 25.26%
2023-11-09 1 $5 $5 $5 $4.391 13.87%

The Trend in the Analyst Price Target


Over the past 20 months, LABP's average price target has gone down $21.17.

LABP reports an average of 713.13% for its upside potential over the past 39 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2023-02-08 2 2 0.1 1.05 0.385 172.73%
2023-05-12 2 10 10.0 10.00 0.298 3255.7%
2023-05-16 2 10 1.0 5.50 0.290 1796.55%
2023-05-16 2 1 0.1 0.55 2.905 -81.07%
2023-11-09 1 5 5.0 5.00 3.830 30.55%

LABP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
3 0 0 1 0 0 1

The Trend in the Broker Recommendations


LABP's average broker recommendation rating improved by 0.5 over the prior 35 weeks.

Use the points listed below to better contextualize what this analyst price target and recommendations data data means for investors.

  • To contextualize these metrics, consider that out of all US stocks, LANDOS BIOPHARMA INC's variance in analysts' estimates is lower than -1922.51% of them.
  • LABP has a higher upside potential (average analyst target price relative to current price) than 1396.02% of all US stocks.
  • LANDOS BIOPHARMA INC's number of analysts covering the stock is greater than 469.74% of Healthcare stocks.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, LANDOS BIOPHARMA INC's average analyst price target is greater than 884.08% of them.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to LANDOS BIOPHARMA INC are TERN, SNSE, and PHVS.

Make investment decisions regarding LABP using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!